Biopharma Plastics

Global Biopharma Plastics Market to Reach US$8.4 Billion by 2030

The global market for Biopharma Plastics estimated at US$5.8 Billion in the year 2024, is expected to reach US$8.4 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Polyethylene, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Polypropylene segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 10.0% CAGR

The Biopharma Plastics market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Biopharma Plastics Market - Key Trends & Drivers Summarized

How Are Biopharma Plastics Revolutionizing the Pharmaceutical Industry?

Biopharma plastics are playing an increasingly vital role in the pharmaceutical and biotechnology industries by enhancing drug production, storage, and delivery efficiency. These high-performance polymers offer superior chemical resistance, biocompatibility, and durability, making them indispensable for biopharmaceutical applications such as single-use bioprocessing systems, medical packaging, and drug delivery devices. The shift toward single-use technologies (SUTs) in biopharmaceutical manufacturing is one of the major factors driving the demand for biopharma plastics, as these materials help mitigate cross-contamination risks, improve process efficiency, and reduce costs. Furthermore, advancements in polymer science are enabling the development of specialized plastics with enhanced barrier properties, ensuring the stability and efficacy of sensitive biologics. As biopharma companies prioritize sustainability, biodegradable and recyclable biopharma plastics are also gaining traction, paving the way for more environmentally friendly solutions within the sector.

Why Is There an Increasing Demand for Single-Use Biopharma Plastics?

The biopharmaceutical industry is witnessing an unprecedented shift toward single-use technologies, significantly boosting the demand for biopharma plastics. Single-use systems (SUS) are being widely adopted for upstream and downstream bioprocessing due to their cost-effectiveness, reduced risk of contamination, and flexibility in manufacturing. The COVID-19 pandemic accelerated the adoption of SUS as pharmaceutical companies sought rapid and scalable production solutions for vaccines and biologics. Materials such as polyethylene (PE), polyvinyl chloride (PVC), polypropylene (PP), and polycarbonate (PC) are extensively used in disposable bioprocessing bags, tubing, bioreactors, and filtration systems. These plastics offer excellent sterilization capabilities, chemical resistance, and mechanical stability, making them ideal for high-purity biopharmaceutical applications. Additionally, with stringent regulatory frameworks emphasizing patient safety and product integrity, manufacturers are focusing on developing advanced polymer formulations that comply with FDA and EMA guidelines, ensuring optimal performance in biopharmaceutical processes.

How Are Regulatory Standards and Industry Innovations Influencing the Market?

The biopharma plastics market is shaped by a combination of evolving regulatory standards, technological innovations, and strategic industry collaborations. Regulatory agencies such as the U.S. FDA and the European Medicines Agency (EMA) have established stringent guidelines for the use of plastics in pharmaceutical applications, particularly concerning extractables and leachables (E&L) testing. Compliance with these regulations is essential to ensure patient safety and maintain drug efficacy. Concurrently, industry players are investing heavily in research and development to enhance the performance of biopharma plastics, focusing on high-purity materials with reduced levels of leachables and improved sterilization capabilities. Furthermore, collaborations between biopharmaceutical firms, plastic manufacturers, and academic institutions are fostering the development of next-generation materials with superior mechanical, thermal, and chemical properties. As sustainability concerns grow, the industry is also exploring bioplastic alternatives derived from renewable sources, aiming to reduce the environmental footprint of biopharmaceutical production while maintaining high product performance.

What Are the Key Drivers Fueling the Growth of the Biopharma Plastics Market?

The growth in the biopharma plastics market is driven by several factors, including the increasing adoption of single-use bioprocessing technologies, advancements in polymer engineering, and the rising demand for biologics and biosimilars. The shift toward personalized medicine and cell and gene therapies has heightened the need for high-performance plastics that ensure the safety and integrity of advanced therapeutics. Additionally, the growing prevalence of chronic diseases and the subsequent rise in biopharmaceutical production have further propelled market demand. The expanding global healthcare infrastructure, particularly in emerging economies, has also contributed to the increasing adoption of biopharma plastics in medical packaging and drug delivery systems. Moreover, the push for greener alternatives and recyclable plastics is encouraging manufacturers to develop innovative solutions that align with sustainability goals while maintaining the high-quality standards required by the pharmaceutical sector. As regulatory requirements become more stringent and the industry moves toward more efficient and flexible manufacturing processes, the biopharma plastics market is expected to experience sustained growth in the years to come.

SCOPE OF STUDY:

The report analyzes the Biopharma Plastics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Polyethylene, Polypropylene, Acrylonitrile Butadiene Styrene, Polyethylene Terephthalate, Polyvinyl Chloride, Polytetrafluoroethylene, Polycarbonate, Other Product Types); Application (Protective Wear Application, Containers Application, Bioreactor Bags Application, Syringes Application, Depth Filters Application, Disposable Medical Connectors Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• AptarGroup
• BASF SE
• Bormioli Pharma S.p.A.
• Catalent, Inc.
• Celanese Corporation
• Chevron Phillips Chemical Co., LLC
• Covestro AG
• Dow, Inc.
• DuPont de Nemours, Inc.
• Exxon Mobil Corporation
• Formosa Plastics Corporation
• Gerresheimer AG
• INEOS Group
• LG Chem
• LyondellBasell Industries Holdings B.V.
• Mitsui & Co. Plastics Ltd.
• Nemera
• Ompi s.r.l.
• Plastipak Holdings, Inc.
• Schott AG
• SiO2 Medical Products
• Solvay SA
• Spectrum Plastics Group
• Stevanato Group Company
• Teijin Ltd.
• Tekni-Plex, Inc.
• Toray Industries, Inc.
• West Pharmaceutical Services, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.